Skip to content

Biohaven BHVN Return on equity

Return on equity at other companies

Eli Lilly logo
Eli LillyLLY
107.6%+29.9pp
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-37.5%+8.7pp
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-28.3%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
-47.7%+3.6pp
uniQure logo
uniQureQURE
-228.2%-11.6pp
Roivant Sciences logo
Roivant SciencesROIV
-17.1%-17.7pp

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.23B-48.1%
Enterprise value$2.23B-46.3%

Returns & leverage

See full
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Calculated from Biohaven’s reported figures.

Based on trailing twelve months.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's return on equity?
Biohaven (BHVN) reported return on equity of -333% in Q1 2026.
How has Biohaven's return on equity changed year-over-year?
Biohaven's return on equity decreased by 5.1% year-over-year, from -316.8% to -333%.
What is the long-term trend for Biohaven's return on equity?
Over 4 years (2021 to 2025), Biohaven's return on equity has grown at a -21.8% compound annual growth rate (CAGR), from -830.7% to -310.8%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.